Surgical Innovation Associates (SIA) develops the DuraSorb® product family, a next-generation bioabsorbable monofilament mesh that provides mechanical support during early wound healing and gradually resorbs over about one year. DuraSorb is commercially available in the U.S. under 510(k) clearance and in Europe under a CE mark, and the company reports robust product adoption and favorable customer feedback. SIA is running a pivotal trial for prosthetic breast reconstruction under an FDA Investigational Device Exemption. The company aims to expand enrollment in that pivotal trial and to develop additional products and indications within the DuraSorb family. Leadership changes — including the May 2021 hire of CEO Josh Vose, MD, MBA — are intended to accelerate commercialization and clinical development. Financially, SIA recently completed a Series B financing as it continues to scale commercially from its 2016 founding in Chicago. Surgical Innovation Associates focuses on developing and commercializing medical products for reconstructive and aesthetic surgery and is led by CEO and co-founder Alexei Mlodinow. Its DuraSorb® product line progressed from ideation through FDA 510(k) clearance into operating-room use. DuraSorb Monofilament Mesh is designed to integrate into patient tissue, provide strong support during early healing, and then slowly dissolve within one year. The company plans to investigate and develop additional products and indications, including breast reconstruction and facial aesthetic applications. SIA intends to use the funds to finance early commercial efforts, pursue further regulatory approvals, and continue product development. Founded in 2016 and based in Chicago, the company has raised $6.5M to date.

Total raised

$19M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2021